Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Aim Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Cauca...
Saved in:
Published in | Investigational new drugs Vol. 42; no. 1; pp. 80 - 88 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
01.02.2024
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.
Methods
In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.
Results
Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (C
max
) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUC
last
) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in C
max
(
P
-value = 0.45) or AUC
last
(
P
-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.
Conclusion
The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased C
max
in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states. |
---|---|
AbstractList | Aim
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.
Methods
In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.
Results
Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (C
max
) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUC
last
) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in C
max
(
P
-value = 0.45) or AUC
last
(
P
-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.
Conclusion
The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased C
max
in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states. Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects. In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing. Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (C ) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUC ) of venadaparib for the fed to fasted state were 0.82 (0.7457-0.9094) and 1.02 (0.9088-1.1339) in Koreans, and 0.77 (0.6871-0.8609) and 0.96 (0.9017-1.0186) in Caucasians, respectively. No statistically significant differences were observed in C (P-value = 0.45) or AUC (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated. The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased C in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states. Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.AIMVenadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.METHODSIn this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457-0.9094) and 1.02 (0.9088-1.1339) in Koreans, and 0.77 (0.6871-0.8609) and 0.96 (0.9017-1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.RESULTSTwelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457-0.9094) and 1.02 (0.9088-1.1339) in Koreans, and 0.77 (0.6871-0.8609) and 0.96 (0.9017-1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.CONCLUSIONThe overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states. AimVenadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects.MethodsIn this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing.ResultsTwelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated.ConclusionThe overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states. |
Author | Ha, Kyoung Soo Jang, In-Jin Lee, Won Sik Yu, Kyung-Sang Yang, Eunsol Kim, Hyun Chul Lee, Soyoung Lee, Myongjae Oh, Jaeseong Lee, ChaeEun |
Author_xml | – sequence: 1 givenname: Hyun Chul orcidid: 0000-0002-8819-4780 surname: Kim fullname: Kim, Hyun Chul organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Integrated Major in Innovative Medical Science, Seoul National University Graduate School – sequence: 2 givenname: Eunsol orcidid: 0000-0003-2581-349X surname: Yang fullname: Yang, Eunsol organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco – sequence: 3 givenname: Soyoung orcidid: 0000-0001-5799-4489 surname: Lee fullname: Lee, Soyoung organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Kidney Research Institute, Seoul National University Medical Research Center – sequence: 4 givenname: Jaeseong orcidid: 0000-0001-6275-8587 surname: Oh fullname: Oh, Jaeseong organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Department of Pharmacology, Jeju National University College of Medicine – sequence: 5 givenname: Myongjae orcidid: 0000-0002-0306-6908 surname: Lee fullname: Lee, Myongjae organization: Idience Co., Ltd – sequence: 6 givenname: ChaeEun orcidid: 0009-0005-4285-4439 surname: Lee fullname: Lee, ChaeEun organization: Idience Co., Ltd – sequence: 7 givenname: Kyoung Soo orcidid: 0000-0002-1216-7516 surname: Ha fullname: Ha, Kyoung Soo organization: Idience Inc – sequence: 8 givenname: Won Sik orcidid: 0000-0001-9502-2429 surname: Lee fullname: Lee, Won Sik organization: Idience Co., Ltd – sequence: 9 givenname: In-Jin orcidid: 0000-0002-8384-3139 surname: Jang fullname: Jang, In-Jin organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital – sequence: 10 givenname: Kyung-Sang orcidid: 0000-0003-0921-7225 surname: Yu fullname: Yu, Kyung-Sang email: ksyu@snu.ac.kr organization: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38099989$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks9u1DAQxi1URLeFF-CALHHhsAE7zjrxCVWrUhCVqBCcrYkz2XjJ2ovtVGxfhlett1vKnwMnjzW_75ux_J2QI-cdEvKcs9ecsfpN5EyKumClKBiv2KK4eURmfFHnq6zkEZkxLutCKlUfk5MY14wxoerqCTkWDVNKNWpGfp73PZoUqe9p731HwXUU0-CssWlHvaNpQLodIGzA-G_WYbLmjr5GBx1sIdh2ToE6_JGKFToMkGyWXZ19vqLWDba1yYd5LumAMKZhRz_6gODmdAmTgWj35X7qcsjuEekGRqRxatf7vZ6Sxz2MEZ_dn6fk67vzL8v3xeWniw_Ls8vCVKVMRcmRg6mNVDWwtumg6xtlOhCLRaVQ9qzFVpZNJ9qmkqBASVWWsjVM9YwbWYtT8vbgu53aDXYGXQow6m2wGwg77cHqvzvODnrlrzVnjeIlr7LDq3uH4L9PGJPe2GhwHMGhn6IuFStVzZtSZPTlP-jaT8Hl92VKcLYQTMpMvfhzpYddfn1eBsoDYIKPMWD_gHCm9wnRh4TonBB9lxB9k0XiIIoZdisMv2f_R3ULd7_AzQ |
Cites_doi | 10.1002/bies.20085 10.4161/spmg.24194 10.1007/s00280-017-3512-5 10.1016/j.maturitas.2015.01.015 10.1016/j.eclinm.2019.10.001 10.1158/1535-7163.MCT-22-0068 10.3945/ajcn.2008.27335 10.1038/s41573-020-0076-6 10.1016/j.jsps.2013.02.003 10.1016/j.ygyno.2021.03.015 10.1007/s00280-015-2836-2 10.1007/s11523-021-00796-4 10.3390/nu10080999 10.1139/o05-038 10.1002/cpt.610 10.1038/nrclinonc.2014.163 10.1093/annonc/mdz192 10.1016/S1470-2045(18)30786-1 10.3390/cancers15020448 10.1038/s41568-022-00535-5 10.1038/clpt.2008.141 10.1158/1078-0432.CCR-22-0442 10.1007/s00412-013-0442-9 10.1016/j.autneu.2006.07.011 10.1517/17425255.2012.657626 10.1016/j.chembiol.2021.02.004 10.1016/j.ygyno.2022.01.032 10.1093/jncimonographs/lgi002 10.1007/s40262-022-01167-6 10.1016/j.ejps.2019.04.003 10.1002/cpt.61 10.1111/bcp.15035 10.4162/nrp.2015.9.3.288 10.1186/s40543-023-00373-6 |
ContentType | Journal Article |
Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION NPM 3V. 7QO 7RV 7WY 7WZ 7X7 7XB 87Z 88E 8AO 8FD 8FI 8FJ 8FK 8FL ABUWG AFKRA AZQEC BENPR BEZIV CCPQU DWQXO FR3 FRNLG FYUFA F~G GHDGH K60 K6~ K9- K9. KB0 L.- M0C M0R M0S M1P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQBIZ PQBZA PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
DOI | 10.1007/s10637-023-01405-z |
DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts Nursing & Allied Health Database ABI/INFORM Collection ABI/INFORM Global (PDF only) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ABI/INFORM Collection Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ABI/INFORM Collection (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Business Premium Collection ProQuest One ProQuest Central Korea Engineering Research Database Business Premium Collection (Alumni) Health Research Premium Collection ABI/INFORM Global (Corporate) Health Research Premium Collection (Alumni) ProQuest Business Collection (Alumni Edition) ProQuest Business Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ABI/INFORM Professional Advanced ABI/INFORM Global Consumer Health Database ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Business ProQuest One Business (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed ABI/INFORM Global (Corporate) ProQuest Business Collection (Alumni Edition) ProQuest One Business Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ABI/INFORM Complete ProQuest Central ABI/INFORM Professional Advanced ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ABI/INFORM Complete (Alumni Edition) Business Premium Collection ABI/INFORM Global ABI/INFORM Global (Alumni Edition) ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Business Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Business (Alumni) ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) Business Premium Collection (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic ABI/INFORM Global (Corporate) |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1573-0646 |
EndPage | 88 |
ExternalDocumentID | PMC10891214 38099989 10_1007_s10637_023_01405_z |
Genre | Journal Article |
GrantInformation_xml | – fundername: Idience Co., Ltd. |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 203 28- 29J 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3SX 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7RV 7WY 7X7 88E 8AO 8FI 8FJ 8FL 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BEZIV BGNMA BKEYQ BKNYI BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRNLG FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GROUPED_ABI_INFORM_COMPLETE GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K60 K6~ K9- KDC KOV KOW KPH LAK LLZTM M0C M0R M1P M4Y MA- MK0 N2Q NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQBIZ PQBZA PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW YLTOR Z45 Z7U Z81 Z82 Z87 Z8O Z8U Z8V Z91 ZGI ZMTXR ZOVNA ~A9 ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ NPM PJZUB PPXIY 7QO 7XB 8FD 8FK FR3 K9. L.- P64 PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c426t-21e1ac7c697a0b8dadf89cda35549e6f0beb628d3b846a9a969226bc09f01c673 |
IEDL.DBID | U2A |
ISSN | 0167-6997 1573-0646 |
IngestDate | Thu Aug 21 18:35:15 EDT 2025 Fri Jul 11 08:59:05 EDT 2025 Sat Aug 23 12:33:38 EDT 2025 Mon Jul 21 06:09:04 EDT 2025 Tue Jul 01 03:15:35 EDT 2025 Fri Feb 21 02:40:31 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Ethnic effect Food effect Pharmacokinetics PARP inhibitor Venadaparib |
Language | English |
License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c426t-21e1ac7c697a0b8dadf89cda35549e6f0beb628d3b846a9a969226bc09f01c673 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
ORCID | 0000-0002-8819-4780 0000-0002-1216-7516 0000-0003-0921-7225 0000-0001-5799-4489 0000-0001-6275-8587 0000-0003-2581-349X 0000-0002-8384-3139 0000-0002-0306-6908 0000-0001-9502-2429 0009-0005-4285-4439 |
OpenAccessLink | https://link.springer.com/10.1007/s10637-023-01405-z |
PMID | 38099989 |
PQID | 2931053066 |
PQPubID | 37283 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10891214 proquest_miscellaneous_2902971823 proquest_journals_2931053066 pubmed_primary_38099989 crossref_primary_10_1007_s10637_023_01405_z springer_journals_10_1007_s10637_023_01405_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-02-01 |
PublicationDateYYYYMMDD | 2024-02-01 |
PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: United States |
PublicationSubtitle | Novel Anti-Cancer Therapeutics and Therapies |
PublicationTitle | Investigational new drugs |
PublicationTitleAbbrev | Invest New Drugs |
PublicationTitleAlternate | Invest New Drugs |
PublicationYear | 2024 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | Ramamoorthy, Pacanowski, Bull (CR24) 2015; 97 Wagar, Mojdehbakhsh, Godecker (CR36) 2022; 165 Shetty, Meistrich (CR19) 2005; 34 Curtin, Szabo (CR7) 2020; 19 Lee, Je, Kim (CR10) 2023; 22 Ame, Spenlehauer, De Murcia (CR4) 2004; 26 CR16 CR15 Moore, Zhang, Agarwal (CR27) 2018; 81 Tallis, Morra, Barkauskaite (CR11) 2014; 123 Sonnenblick, De Azambuja, Azim (CR3) 2015; 12 CR33 CR32 CR31 CR30 Maljaars, Romeyn, Haddeman (CR38) 2009; 89 Nicum, Blagden (CR35) 2022; 28 Lafargue, Dal Molin, Sood (CR17) 2019; 20 Jiang, Tao, Liu (CR28) 2022; 88 Konecny, Oza, Tinker (CR29) 2021; 161 Kim, Chen, Yu (CR12) 2021; 28 Mcgraw, Waller (CR34) 2012; 8 Chung, Lee, Lee (CR39) 2015; 9 Malanga, Althaus (CR5) 2005; 83 Mateo, Lord, Serra (CR9) 2019; 30 Koziolek, Alcaro, Augustijns (CR23) 2019; 134 Ovejero-Sanchez, Gonzalez-Sarmiento, Herrero (CR2) 2023; 15 Celik-Ozenci, Tasatargil (CR18) 2013; 3 Groelly, Fawkes, Dagg (CR1) 2023; 23 Cortesi, Rugo, Jackisch (CR8) 2021; 16 Bruin, Sonke, Beijnen (CR25) 2022; 61 Bischoff, Renzer (CR37) 2006; 129 CR22 CR21 Gaal, Kerr, Ward (CR40) 2018; 10 Yasuda, Zhang, Huang (CR14) 2008; 84 CR20 Plummer, Swaisland, Leunen (CR26) 2015; 76 Parsad, Ratain (CR13) 2017; 101 Alomar (CR42) 2014; 22 Tangutoori, Baldwin, Sridhar (CR6) 2015; 81 Watson, Caster, Rochon (CR41) 2019; 17 C Kim (1405_CR12) 2021; 28 K Moore (1405_CR27) 2018; 81 1405_CR15 1405_CR16 M Koziolek (1405_CR23) 2019; 134 JC Ame (1405_CR4) 2004; 26 1405_CR31 SC Bischoff (1405_CR37) 2006; 129 1405_CR32 1405_CR33 R Plummer (1405_CR26) 2015; 76 S Parsad (1405_CR13) 2017; 101 1405_CR30 J Mcgraw (1405_CR34) 2012; 8 C Celik-Ozenci (1405_CR18) 2013; 3 A Sonnenblick (1405_CR3) 2015; 12 S Tangutoori (1405_CR6) 2015; 81 MC Bruin (1405_CR25) 2022; 61 M Ovejero-Sanchez (1405_CR2) 2023; 15 J Maljaars (1405_CR38) 2009; 89 J Mateo (1405_CR9) 2019; 30 M Tallis (1405_CR11) 2014; 123 X Jiang (1405_CR28) 2022; 88 FJ Groelly (1405_CR1) 2023; 23 GE Konecny (1405_CR29) 2021; 161 S Watson (1405_CR41) 2019; 17 M Malanga (1405_CR5) 2005; 83 S Nicum (1405_CR35) 2022; 28 NJ Curtin (1405_CR7) 2020; 19 G Shetty (1405_CR19) 2005; 34 1405_CR20 1405_CR21 1405_CR22 A Ramamoorthy (1405_CR24) 2015; 97 CJ Lafargue (1405_CR17) 2019; 20 S Gaal (1405_CR40) 2018; 10 MJ Alomar (1405_CR42) 2014; 22 M Lee (1405_CR10) 2023; 22 SJ Chung (1405_CR39) 2015; 9 SU Yasuda (1405_CR14) 2008; 84 MK Wagar (1405_CR36) 2022; 165 L Cortesi (1405_CR8) 2021; 16 |
References_xml | – volume: 26 start-page: 882 year: 2004 end-page: 893 ident: CR4 article-title: The PARP superfamily publication-title: BioEssays doi: 10.1002/bies.20085 – volume: 3 start-page: e24194 year: 2013 ident: CR18 article-title: Role of poly(ADP-ribose) polymerases in male reproduction publication-title: Spermatogenesis doi: 10.4161/spmg.24194 – ident: CR22 – volume: 81 start-page: 497 year: 2018 end-page: 503 ident: CR27 article-title: The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent Ovarian cancer publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-017-3512-5 – volume: 81 start-page: 5 year: 2015 end-page: 9 ident: CR6 article-title: PARP inhibitors: a new era of targeted therapy publication-title: Maturitas doi: 10.1016/j.maturitas.2015.01.015 – volume: 17 start-page: 100188 year: 2019 ident: CR41 article-title: Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2019.10.001 – volume: 22 start-page: 333 year: 2023 end-page: 342 ident: CR10 article-title: Venadaparib is a novel and selective PARP inhibitor with Improved Physicochemical Properties, Efficacy, and Safety publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-22-0068 – volume: 89 start-page: 1019 year: 2009 end-page: 1024 ident: CR38 article-title: Effect of fat saturation on satiety, hormone release, and food intake publication-title: Am J Clin Nutr doi: 10.3945/ajcn.2008.27335 – ident: CR16 – volume: 19 start-page: 711 year: 2020 end-page: 736 ident: CR7 article-title: Poly(ADP-ribose) polymerase inhibition: past, present and future publication-title: Nat Rev Drug Discovery doi: 10.1038/s41573-020-0076-6 – ident: CR30 – ident: CR33 – volume: 22 start-page: 83 year: 2014 end-page: 94 ident: CR42 article-title: Factors affecting the development of adverse drug reactions (review article) publication-title: Saudi Pharm J doi: 10.1016/j.jsps.2013.02.003 – volume: 161 start-page: 668 year: 2021 end-page: 675 ident: CR29 article-title: Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2021.03.015 – volume: 76 start-page: 723 year: 2015 end-page: 729 ident: CR26 article-title: Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-015-2836-2 – volume: 16 start-page: 255 year: 2021 end-page: 282 ident: CR8 article-title: An overview of PARP inhibitors for the treatment of Breast Cancer publication-title: Target Oncol doi: 10.1007/s11523-021-00796-4 – volume: 10 start-page: 999 year: 2018 ident: CR40 article-title: Breakfast consumption in the UK: patterns, nutrient intake and Diet Quality. A study from the International Breakfast Research Initiative Group publication-title: Nutrients doi: 10.3390/nu10080999 – volume: 83 start-page: 354 year: 2005 end-page: 364 ident: CR5 article-title: The role of poly(ADP-ribose) in the DNA damage signaling network publication-title: Biochem Cell Biol doi: 10.1139/o05-038 – volume: 101 start-page: 606 year: 2017 end-page: 612 ident: CR13 article-title: Food Effect studies for Oncology Drug products publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.610 – volume: 12 start-page: 27 year: 2015 end-page: 41 ident: CR3 article-title: An update on PARP inhibitors–moving to the adjuvant setting publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2014.163 – volume: 30 start-page: 1437 year: 2019 end-page: 1447 ident: CR9 article-title: A decade of clinical development of PARP inhibitors in perspective publication-title: Ann Oncol doi: 10.1093/annonc/mdz192 – volume: 20 start-page: e15 year: 2019 end-page: e28 ident: CR17 article-title: Exploring and comparing adverse events between PARP inhibitors publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30786-1 – volume: 15 start-page: 448 year: 2023 ident: CR2 article-title: DNA damage response alterations in Ovarian Cancer: from Molecular mechanisms to Therapeutic opportunities publication-title: Cancers (Basel) doi: 10.3390/cancers15020448 – ident: CR21 – volume: 23 start-page: 78 year: 2023 end-page: 94 ident: CR1 article-title: Targeting DNA damage response pathways in cancer publication-title: Nat Rev Cancer doi: 10.1038/s41568-022-00535-5 – volume: 84 start-page: 417 year: 2008 end-page: 423 ident: CR14 article-title: The role of ethnicity in variability in response to Drugs: focus on clinical pharmacology studies publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.141 – volume: 28 start-page: 2201 year: 2022 end-page: 2203 ident: CR35 article-title: PARPs: all for one and one for all? Enhancing diversity in clinical trials publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-22-0442 – ident: CR15 – volume: 123 start-page: 79 year: 2014 end-page: 90 ident: CR11 article-title: Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response publication-title: Chromosoma doi: 10.1007/s00412-013-0442-9 – volume: 129 start-page: 22 year: 2006 end-page: 27 ident: CR37 article-title: Nausea and nutrition publication-title: Auton Neurosci doi: 10.1016/j.autneu.2006.07.011 – ident: CR31 – volume: 8 start-page: 371 year: 2012 end-page: 382 ident: CR34 article-title: Cytochrome P450 variations in different ethnic populations publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.2012.657626 – volume: 28 start-page: 456 year: 2021 end-page: 462 ident: CR12 article-title: Avoid the trap: Targeting PARP1 beyond human malignancy publication-title: Cell Chem Biol doi: 10.1016/j.chembiol.2021.02.004 – volume: 165 start-page: 49 year: 2022 end-page: 52 ident: CR36 article-title: Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2022.01.032 – volume: 34 start-page: 36 year: 2005 end-page: 39 ident: CR19 article-title: Hormonal approaches to preservation and restoration of male fertility after cancer treatment publication-title: J Natl Cancer Inst Monogr doi: 10.1093/jncimonographs/lgi002 – volume: 61 start-page: 1649 year: 2022 end-page: 1675 ident: CR25 article-title: Pharmacokinetics and pharmacodynamics of PARP inhibitors in Oncology publication-title: Clin Pharmacokinet doi: 10.1007/s40262-022-01167-6 – ident: CR32 – volume: 134 start-page: 31 year: 2019 end-page: 59 ident: CR23 article-title: The mechanisms of pharmacokinetic food-drug interactions - a perspective from the UNGAP group publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2019.04.003 – volume: 97 start-page: 263 year: 2015 end-page: 273 ident: CR24 article-title: Racial/ethnic differences in drug disposition and response: review of recently approved Drugs publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.61 – volume: 88 start-page: 1087 year: 2022 end-page: 1093 ident: CR28 article-title: A randomized, open-label, two-period crossover bridging study on fuzuloparib capsules of different specifications in healthy Chinese volunteers publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.15035 – volume: 9 start-page: 288 year: 2015 end-page: 295 ident: CR39 article-title: Breakfast skipping and breakfast type are associated with daily nutrient intakes and metabolic syndrome in Korean adults publication-title: Nutr Res Pract doi: 10.4162/nrp.2015.9.3.288 – ident: CR20 – volume: 101 start-page: 606 year: 2017 ident: 1405_CR13 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.610 – volume: 19 start-page: 711 year: 2020 ident: 1405_CR7 publication-title: Nat Rev Drug Discovery doi: 10.1038/s41573-020-0076-6 – volume: 22 start-page: 333 year: 2023 ident: 1405_CR10 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-22-0068 – volume: 76 start-page: 723 year: 2015 ident: 1405_CR26 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-015-2836-2 – volume: 8 start-page: 371 year: 2012 ident: 1405_CR34 publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425255.2012.657626 – ident: 1405_CR22 – volume: 165 start-page: 49 year: 2022 ident: 1405_CR36 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2022.01.032 – ident: 1405_CR21 doi: 10.1186/s40543-023-00373-6 – volume: 123 start-page: 79 year: 2014 ident: 1405_CR11 publication-title: Chromosoma doi: 10.1007/s00412-013-0442-9 – volume: 34 start-page: 36 year: 2005 ident: 1405_CR19 publication-title: J Natl Cancer Inst Monogr doi: 10.1093/jncimonographs/lgi002 – ident: 1405_CR15 – volume: 22 start-page: 83 year: 2014 ident: 1405_CR42 publication-title: Saudi Pharm J doi: 10.1016/j.jsps.2013.02.003 – volume: 84 start-page: 417 year: 2008 ident: 1405_CR14 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2008.141 – volume: 28 start-page: 456 year: 2021 ident: 1405_CR12 publication-title: Cell Chem Biol doi: 10.1016/j.chembiol.2021.02.004 – ident: 1405_CR32 – volume: 83 start-page: 354 year: 2005 ident: 1405_CR5 publication-title: Biochem Cell Biol doi: 10.1139/o05-038 – ident: 1405_CR30 – volume: 28 start-page: 2201 year: 2022 ident: 1405_CR35 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-22-0442 – volume: 10 start-page: 999 year: 2018 ident: 1405_CR40 publication-title: Nutrients doi: 10.3390/nu10080999 – volume: 15 start-page: 448 year: 2023 ident: 1405_CR2 publication-title: Cancers (Basel) doi: 10.3390/cancers15020448 – ident: 1405_CR33 – volume: 89 start-page: 1019 year: 2009 ident: 1405_CR38 publication-title: Am J Clin Nutr doi: 10.3945/ajcn.2008.27335 – volume: 9 start-page: 288 year: 2015 ident: 1405_CR39 publication-title: Nutr Res Pract doi: 10.4162/nrp.2015.9.3.288 – volume: 30 start-page: 1437 year: 2019 ident: 1405_CR9 publication-title: Ann Oncol doi: 10.1093/annonc/mdz192 – volume: 12 start-page: 27 year: 2015 ident: 1405_CR3 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2014.163 – volume: 16 start-page: 255 year: 2021 ident: 1405_CR8 publication-title: Target Oncol doi: 10.1007/s11523-021-00796-4 – volume: 97 start-page: 263 year: 2015 ident: 1405_CR24 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.61 – volume: 88 start-page: 1087 year: 2022 ident: 1405_CR28 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.15035 – volume: 20 start-page: e15 year: 2019 ident: 1405_CR17 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30786-1 – ident: 1405_CR20 – volume: 81 start-page: 497 year: 2018 ident: 1405_CR27 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-017-3512-5 – volume: 161 start-page: 668 year: 2021 ident: 1405_CR29 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2021.03.015 – volume: 129 start-page: 22 year: 2006 ident: 1405_CR37 publication-title: Auton Neurosci doi: 10.1016/j.autneu.2006.07.011 – volume: 61 start-page: 1649 year: 2022 ident: 1405_CR25 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-022-01167-6 – volume: 23 start-page: 78 year: 2023 ident: 1405_CR1 publication-title: Nat Rev Cancer doi: 10.1038/s41568-022-00535-5 – volume: 3 start-page: e24194 year: 2013 ident: 1405_CR18 publication-title: Spermatogenesis doi: 10.4161/spmg.24194 – volume: 17 start-page: 100188 year: 2019 ident: 1405_CR41 publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2019.10.001 – volume: 134 start-page: 31 year: 2019 ident: 1405_CR23 publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2019.04.003 – volume: 26 start-page: 882 year: 2004 ident: 1405_CR4 publication-title: BioEssays doi: 10.1002/bies.20085 – volume: 81 start-page: 5 year: 2015 ident: 1405_CR6 publication-title: Maturitas doi: 10.1016/j.maturitas.2015.01.015 – ident: 1405_CR16 – ident: 1405_CR31 |
SSID | ssj0003974 |
Score | 2.3812542 |
Snippet | Aim
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the... Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects... AimVenadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the... |
SourceID | pubmedcentral proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 80 |
SubjectTerms | Dosage Ethnicity Food Gastric cancer Inhibitors Labels Males Medicine Medicine & Public Health Minority & ethnic groups Oncology Oral administration Pharmacokinetics Pharmacology/Toxicology Poly(ADP-ribose) Poly(ADP-ribose) polymerase Ribose Statistical analysis Targeted cancer therapy Time measurement White people |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgien5VTxlB7sUG2203H09yHB6HoixyB_tWkiZxl8N0ve4-7P0z_qvOtN1d1kPfAkmThplkfslMfsPYu7GzdWF1wRG7Ol4KE7jJ64zrzMjSWh1C6AJkv4nzy_LzdDwdLtzaIaxysyd2G7Vraroj_4BmCaEAAlzxcfGLU9Yo8q4OKTTusntEXUYhXXK6PXBlaGu33N5Cazk8mhmezolCcrRYnM4YY36zb5huoc3bQZN_eU47g3T2iD0ckCSc9KJ_zO74eMjufx185YfseNKzUq9TuNg9smpTOIbJjq96_YT97hmMW2gChKZxYKIDv5xF7Gi5hiYCgkRYDN9cYefUD7XGjdI4Q3kMbQoGIp2if3Q81iRumJx8n8A8zuYWt43rFIvQP7tcw5cGwWpM4dRQ0rU5FWlUyubtWw8_0WxBu7J0SdQ-ZZdnny5Oz_mQt4HXaO-XfJT73NSyFlqazCpnXFC6doagjfYiZNZbMVKusAh-jDZaaASBts50yPJayOIZO4hN9C8Y5KFQMmSF9UKVY6PVWDrKUCNdKaWqdcLeb4RWLXp6jmpHxEwirlDEVSfi6iZhRxu5VsNSbaudYiXs7bYaFxl5Tkz0zYraUI4vVOciYc97NdgOVygC2Qp_Re0pyLYBEXjv18T5rCPyzjOl81FeJizd6NLuv_49jZf_n8Yr9mCEyKsPLT9iB8vrlX-NyGlp33TL4w_fdxf5 priority: 102 providerName: ProQuest |
Title | Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects |
URI | https://link.springer.com/article/10.1007/s10637-023-01405-z https://www.ncbi.nlm.nih.gov/pubmed/38099989 https://www.proquest.com/docview/2931053066 https://www.proquest.com/docview/2902971823 https://pubmed.ncbi.nlm.nih.gov/PMC10891214 |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfYJiFeEIyvwqiMhPZCIiVN4o_HtmqZmKiqaZXKU2TH9lohnGlpH7p_hn-VuyRtKYMHnmzJjuPozr7fxb7fEfIxM7pItExCwK4mTJlyoYqLKJSR4qnW0jlXX5CdsItZ-mWezdugsGp72317JFnv1L8Fu7GEh2BjQvQKsvD-iJxk6LuDFs96_d3-CxZ2x-jNpORtqMzfxzg0Rw8w5sOrkn-cl9ZmaPyMPG3xI-03An9OHll_Sh5_bU_IT8n5tOGi3gT0eh9aVQX0nE73LNWbF-Rnw1tc0dJRV5aGKm-oXS08DLTa0NJTgIb0tn3mOwyO42Bv2B6VUZi9UAdUUY--803NXo1CptP-1ZQu_WKpYbO4C6BKm2DLDb0sAaL6gA4VplpbYhXfijm8bWXpDzBWtFpr_DVUvSSz8eh6eBG22RrCAqz8KuzFNlYFL5jkKtLCKOOELIxCQCMtc5G2mvWESTRAHiWVZBKgny4i6aK4YDx5RY596e0bQmOXCO6iRFsm0kxJkXGDeWm4STkXheyQT1uh5bcNKUe-p19GEecg4rwWcX7fIWdbuebtAq1yQDmALMFfYh3yYdcMSwvPS5S35Rr7YGYvUOKkQ143arB7XSIQWguYijhQkF0HpO0-bPHLRU3fHUdCxr047ZBgq0v7ef37M97-X_d35AmsjbS5YH5Gjld3a_se8NNKd8kRn_MuOemPB4MJlp-_XY6gHIwm0ytoHbJht15SvwDmpRvW |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2VVAJeEJRboMAgQV-whW-xdx8QKqVVS9ooqlKpb-6ud00ixDrUiVD6M_wB38iML4lCBW99s-T12tbMzjl7mTOMvelplYVKhC5yV-1Gscxd6WeeKzyZREqJPM-rA7KD-PAs-nLeO99gv9tcGDpW2cbEKlDrIqM18vcIS0gFkODGH6c_XKoaRburbQmN2i36ZvETp2zlh6PPaN-3QXCwP9o7dJuqAm6GaDRzA9_4MkuyWCTSU1xLnXORaUnAK0yce8qoOOA6VAjNUkgRC6QoKvNE7vlZnITY7y22GYU4lemwzU_7g-HpMvYjui_VxGMhkiZNp0nWi8PERYx0aVbTc6_WofAav71-TPOvvdoKAg_us3sNd4Xd2tkesA1jt9jtk2Z3fovtDGsd7IUDo1VaV-nADgxXCtmLh-xXrZlcQpFDXhQapNVgZmOLHc0WUFhAWgrT5plv2Dn1Q60xNEstqXKickCCpXn710o5mxwMhrunQ5jY8URhoLp08BLqRM8F9Aukx9aBPUll3iZ0SW-l-uGmNPAdgRLKuaJlqfIRO7sRmz5mHVtY85SBn4c8yb1QmZhHPSl4L9FUEyfRUZLwTHTZu9Zo6bQWBElX0s9k4hRNnFYmTq-6bLu1a9oEhzJduXKXvV7exmFNezXSmmJObaiqGA6gsMue1G6wfF3IidZz_BS-5iDLBiQZvn7HTsaVdLjvceEHftRlTutLq-_69288-_9vvGJ3Dkcnx-nx0aD_nN0NkPfVB9u3WWd2OTcvkLfN1MtmsAC7uOnx-QdJmlbW |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkCZeEIzLCgOMBHsh0XK3_YDQtFFtFKYKbVLfgh3btJrmlKUV6v4M_4Nfxzm5tCoTvO0tUhwn0bl8n-1zIeRNqlURKxH7wF21n2TS-jIsAl8EkiVKCWttHSB7mh2fJ59G6WiD_O5yYTCssvOJtaPWZYF75PsAS0AFgOBm-7YNixge9T9Mf_jYQQpPWrt2Go2KDMziJyzfqvcnRyDrt1HU_3h2eOy3HQb8ApBp5kehCWXBikwwGSiupbZcFFoiCAuT2UAZlUVcxwpgWgopMgF0RRWBsEFYZCyGee-QuyxOQ7QxNlou9gLA-WVd8UwI1ibstGl7Wcx8QEsf1zepf70OijeY7s2Azb9ObWsw7D8g91sWSw8atXtINozbJltf2nP6bbI3bCpiLzx6tkrwqjy6R4erWtmLR-RXUz25oqWltiw1lU5TMxs7mGi2oKWjQFDptH3mAibHeXA0OGmpJfZQVB6V1OEK_ntdQxtVjQ4Pvg7pxI0nClzWlQeXtEn5XNBBCUTZefRQYsO3CV7iW7GTuKkMvQTIpNVc4QZV9Zic34pEn5BNVzqzQ2hoY85sECuT8SSVgqdMY3ccphPGeCF65F0ntHzalAbJV0WgUcQ5iDivRZxf98huJ9e8dRNVvlLqHnm9vA0Gjqc20plyjmOwvxiYUtwjTxs1WL4u5kjwOXwKX1OQ5QAsHr5-x03GdRHxMOAijMKkR7xOl1bf9e_fePb_33hFtsAq888np4Pn5F4EBLCJcN8lm7OruXkBBG6mXtaWQsm32zbNP2IVWaY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+food+and+ethnicity+on+the+pharmacokinetics+of+venadaparib%2C+a+next-generation+PARP+inhibitor%2C+in+healthy+Korean%2C+Caucasian%2C+and+Chinese+male+subjects&rft.jtitle=Investigational+new+drugs&rft.au=Kim%2C+Hyun+Chul&rft.au=Yang%2C+Eunsol&rft.au=Lee%2C+Soyoung&rft.au=Oh%2C+Jaeseong&rft.date=2024-02-01&rft.pub=Springer+US&rft.issn=0167-6997&rft.eissn=1573-0646&rft.volume=42&rft.issue=1&rft.spage=80&rft.epage=88&rft_id=info:doi/10.1007%2Fs10637-023-01405-z&rft.externalDocID=10_1007_s10637_023_01405_z |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6997&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6997&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6997&client=summon |